Since 5 October, Cerba has been one of the 4 private laboratories selected by the French Public Health Agency to perform SARS-CoV-2 sequencing for epidemic surveillance.
 
Congratulations to Cerba’s teams who have been hard at work on this project for over 6 months. 
 
Every week, as part of the EMERGEN project, the technical team and the Cerba infectiology unit will carry out up to 1000 sequences for epidemiological monitoring of variants at a national level.

Laboratoire Cerba has strong clinical experience in the field of next-generation sequencing (NGS). In 2013, Cerba was a pioneer in developing its screening test for trisomy 13, 18 and 21 by NGS for circulating foetal DNA. Since then, numerous analyses have been carried out routinely in various applications in genetics, oncohaematology and infectiology.